[go: up one dir, main page]

GB0605395D0 - Anti-cancer therapy - Google Patents

Anti-cancer therapy

Info

Publication number
GB0605395D0
GB0605395D0 GBGB0605395.3A GB0605395A GB0605395D0 GB 0605395 D0 GB0605395 D0 GB 0605395D0 GB 0605395 A GB0605395 A GB 0605395A GB 0605395 D0 GB0605395 D0 GB 0605395D0
Authority
GB
United Kingdom
Prior art keywords
cancer therapy
cancer
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0605395.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NORWEGIAN RADIUM HOSPITAL RES
Norwegian Radium Hospital Research Foundation
Original Assignee
NORWEGIAN RADIUM HOSPITAL RES
Norwegian Radium Hospital Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NORWEGIAN RADIUM HOSPITAL RES, Norwegian Radium Hospital Research Foundation filed Critical NORWEGIAN RADIUM HOSPITAL RES
Priority to GBGB0605395.3A priority Critical patent/GB0605395D0/en
Publication of GB0605395D0 publication Critical patent/GB0605395D0/en
Priority to PCT/GB2007/000928 priority patent/WO2007104999A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6829Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0605395.3A 2006-03-16 2006-03-16 Anti-cancer therapy Ceased GB0605395D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0605395.3A GB0605395D0 (en) 2006-03-16 2006-03-16 Anti-cancer therapy
PCT/GB2007/000928 WO2007104999A1 (en) 2006-03-16 2007-03-16 Anti-cancer therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0605395.3A GB0605395D0 (en) 2006-03-16 2006-03-16 Anti-cancer therapy

Publications (1)

Publication Number Publication Date
GB0605395D0 true GB0605395D0 (en) 2006-04-26

Family

ID=36292951

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0605395.3A Ceased GB0605395D0 (en) 2006-03-16 2006-03-16 Anti-cancer therapy

Country Status (2)

Country Link
GB (1) GB0605395D0 (en)
WO (1) WO2007104999A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU619740B2 (en) * 1987-02-24 1992-02-06 Xoma Corporation Immunosuppression in immunotoxin based human therapy
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO2000006194A2 (en) * 1997-02-05 2000-02-10 Biotransplant, Inc. Depletion of cells responsible for antibody-mediated graft rejection

Also Published As

Publication number Publication date
WO2007104999A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
IL196559A0 (en) Combination therapy
GB0610680D0 (en) Therapeutic compounds
GB2436010B (en) Therapy device
IL196556A0 (en) Combination therapy
IL199992A0 (en) Combination therapy
EP2054061A4 (en) Combination therapy
GB0603041D0 (en) Therapeutic compounds
EP2004154A4 (en) Therapeutic belt
GB0719518D0 (en) Therapy
ZA200902203B (en) Combination therapy
GB0606663D0 (en) Therapeutic compounds
IL198026A0 (en) Sequential combination therapy
EP2211863A4 (en) Combination therapy
GB0625783D0 (en) Medicament
GB0700284D0 (en) Combination therapy
GB0603455D0 (en) Therapeutic compounds
GB0615064D0 (en) Medicament
GB0605573D0 (en) Therapeutic Compounds
GB0716072D0 (en) Therapy
GB0700635D0 (en) Therapy
GB0605395D0 (en) Anti-cancer therapy
GB0722015D0 (en) Transdermal therapy
GB0615814D0 (en) Medicament
ZA200708369B (en) Medicament
GB0606660D0 (en) Targeted Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)